Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (PILLAR)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
NewLink Genetics Corporation
ClinicalTrials.gov Identifier:
NCT01836432
First received: April 17, 2013
Last updated: December 21, 2015
Last verified: December 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: June 2017
  Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)